A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A01N 1/02 (2006.01) A61K 35/23 (2006.01) C07K 16/28 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2121235
2121235 9307900 PCTABS00021 In vitro treatment of a kidney prior to transplantation into a human recipient to reduce the risk of rejection, comprises perfusing the kidney with a solution of antibody specific to passenger leukocytes (e.g. anti-CD45 antibody) under cold ischaemia (CI) conditions with the renal vein occluded, and incubating the perfused kidney under CI conditions for at least 20 minutes. The volume of perfusion liquid is preferably at least 50 ml and the concentration of mAb about 40 µg/ml or more. This has been found to increase mAb uptake by the target cells and the extent of mAb saturation of the target cells, and seems to be associated with a reduced incidence of graft rejection.
Goldberg Lawrence C.
Taube Hirsch D.
Bereskin & Parr
Cantab Pharmaceuticals Research Limited
LandOfFree
In vitro antibody perfusion of kidney grafts does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with In vitro antibody perfusion of kidney grafts, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and In vitro antibody perfusion of kidney grafts will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1726179